High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides and effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast cancer

Bone Marrow Transplantation

Volumn 32, Issue 3, 2003, Pages 251-255

  De Giorgi, U ^a   Rosti, G ^a   Zaniboni, A ^b   Ballardini, M ^c   Minzi, M R ^a   Baioni, M ^a   Ferrari, E ^a   Zornetta, L ^a   Marangolo, M ^a  

^a SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^b Oncology Unit   (Italy)

^c ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

Author keywords

Breast cancer; Dexrazoxane; Epirubicin; Filgrastim; Paclitaxel; Stem cell mobilization

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CD33 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CIMETIDINE; CIPROFLOXACIN; DEXAMETHASONE; EPIRUBICIN; ONDANSETRON; ORPHENADRINE; PACLITAXEL; PARACETAMOL; RAZOXANE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BONE PAIN; BREAST CANCER; CELL COUNT; CELL ISOLATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SAFETY; EDEMA; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEVER; HIGH RISK PATIENT; HUMAN; HYPERSENSITIVITY REACTION; LEUKAPHERESIS; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RASH; STEM CELL MOBILIZATION; THROMBOCYTOPENIA; VOMITING;

ADULT; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL COUNT; EPIRUBICIN; FEMALE; FILGRASTIM; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LEUKAPHERESIS; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; RAZOXANE;

EID: 0042168937     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704125     Document Type: Article

References (30)

1. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998; 339: 974-984.
2. Pedrazzoli P, Perotti C, Da Prada GA et al. Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer. Br J Cancer 1997; 75: 1368-1372.
3. Zibera C, Pedrazzoli P, Ponchio L et al. An epirubicin/ paclitaxel combination mobilizes large amounts of hematopoietic progenitor cells in patients with metastatic breast cancer showing optimal response to the same chemotherapy regimen. Haematologica 1999; 84: 924-929.
4. Bengala C, Pazzagli I, Tibaldi C et al. Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte-colony stimulating factor administered to patients with metastatic breast carcinoma. Cancer 1998; 82: 867-873.
5. Rosti G, Albertazzi L, Ferrante P et al. Epirubicin + G-CSF as peripheral blood progenitor cells (PBPC) mobilizing agents in breast cancer patients. Ann Oncol 1995; 6: 1045-1047.
6. Burtness BA, Psyrri A, Rose M et al. A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells. Bone Marrow Transplant 1999; 23: 311-315.
7. Lopez M, Vici P, Di Lauro L et al. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol 1998; 16: 86-92.
8. Hensley ML, Schuchter LM, Lindley C et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17: 3333-3355.
9. Stewart THM, Retsky MW, Tsai SCJ, Verma S. Dose response in the treatment of breast cancer. Lancet 1994; 343: 402-404.
10. Wood WC, Budman DR, Korzun AH et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994; 330: 1253-1259.
11. Bastholt L, Dalmark M, Gjedde SB et al. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 1996; 14: 1146-1155.
12. 2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. Ann Oncol 1997; 8: 155-162.
13. Budman DR, Berry DA, Cirrincione CT et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 1998; 90: 1205-1211.
14. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: five years follow-up results of FASF 05 randomized trial. J Clin Oncol 2000; 19: 602 611.
15. Gianni AM, Siena S, Bregni M et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol 1997; 15: 2312-2321.
16. Basser RL, To LB, Collins JP et al. Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five year follow-up. J Clin Oncol 1999; 17: 82-92.
17. Hudis C, Seidman A, Baselga J et al. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol 1999; 17: 93-100.
18. Lalisang RI, Voest EE, Wils JA et al. Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer. Br J Cancer 2000; 82: 1914-1919.
19. Cottu PH, Extra JM, Espie M et al. High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study. Br J Cancer 2001; 85: 1240-1246.
20. Elias AD, Richardson P, Avigan D et al. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer. Bone Marrow Transplant 2001; 27: 269-278.
21. Schrama JG, Baars JW, Holtkamp MJ et al. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer. Bone Marrow Transplant 2001; 28: 173-180.
22. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70: 163-169.
23. National Cancer Institute Common Toxicity Criteria version 2.0. Http://ctep.cancer.gov/reporting/ctc.html.
24. Peters WP, Ross M, Vrenenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1143.
25. Hasinoff BB, Hellmann K, Herman EH, Ferrans VJ. Chemical biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 1998; 5: 1-28.
26. Tetef ML, Synold TW, Chow W et al. Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies. Clin Cancer Res 2001; 7: 1569-1576.
27. Langer SW, Sehesyed M, Jensen PB. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Ann Oncol 2001; 12: 405-410.
28. Liesmann J, Belt R, Haas C, Hoogstraten B. Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy. Cancer 1981; 47: 1959-1962.
29. Gomez-Espuch J, Moraleda JM, Ortuno F et al. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotherapeutic agent, associated with rhG-CSF. Bone Marrow Transplant 2000; 25: 231-235.
30. Demirer T, Rowley S, Buckner CD et al. Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer. J Clin Oncol 1995; 13: 1714-1719.